Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity

Date Added
December 12th, 2022
PRO Number
Pro00124592
Researcher
Patrick O'Neil

List of Studies


Keywords
Drug Studies, Obesity, Weight Control
Summary

This study is designed to evaluate the efficacy and safety of semaglutide s.c. 7.2 mg once-weekly versus placebo and semaglutide s.c. 2.4 mg once-weekly as an adjunct to reduced-calorie diet and increased physical activity in adults with obesity.

The maximum duration of the study intervention for each participant is 72 weeks and the duration of the study for each participant is 81 weeks.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4mg (CagriSema s.c. 2.4 mg/2.4mg) once-weekly in participants with overweight or obesity

Date Added
October 27th, 2022
PRO Number
Pro00123458
Researcher
Patrick O'Neil

List of Studies


Keywords
Drug Studies, Obesity, Weight Control
Summary

This study is to look at how well the new medicine CagriSema works at assisting weight loss for people with excess body weight, compared to "dummy" medicine and 2 other medicines.

The 68-week main phase of the present study is designed to compare the efficacy and safety of once-weekly cagrilintide in combination with semaglutide versus once-weekly cagrilintide, semaglutide, and placebo, all as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in participants with overweight or obesity.

The study will also include a 97-week off-treatment period for participants in the CagriSema and placebo treatment arms only (extension phase), to obtain a better understanding of the impact of withdrawing the study interventions on weight, cardiovascular risk factors and glucose metabolism in people living with
overweight or obesity.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

The Effect Of Epitomee Capsule On Body Weight In Patients With Overweight And Obesity With And Without Pre-Diabetes

Date Added
August 19th, 2020
PRO Number
Pro00094007
Researcher
Patrick O'Neil

List of Studies


Keywords
Nutrition, Obesity, Weight Control
Summary

This study is testing the effects on weight loss of a capsule-delivered device that expands in the stomach to help create a sense of fullness. The device then leaves the stomach, disintegrates and is excreted. In this study participants will receive either the device or a placebo capsule that looks the same. Participants will receive dietary and exercise counseling at most visits to help them lose weight. The 24-week losses of participants who get the device will be compared to the losses of those who get the placebo capsule to determine the effect on weight loss. Changes in other health markers will also be assessed.

Institution
MUSC
Recruitment Contact
Mary Harley
843-792-5428
harleyma@musc.edu

A Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma

Date Added
February 28th, 2017
PRO Number
Pro00062918
Researcher
David Koch

List of Studies


Keywords
Cancer, Cancer/Gastrointestinal, Cancer/Other, Digestive System, Genetics, Liver, Obesity, Weight Control
Summary

TARGET-HCC is a 15-year, longitudinal, observational study of the natural history and management of patients with HCC. The study will address important clinical questions that remain unanswered in the management of HCC with a unique research registry of participants with HCC from academic and community real-world practices. TARGET-HCC is disease focused, not drug specific, which allows for continuous acquisition of real-world evidence regarding the natural history, management, and outcomes of treatment with current therapies and new treatments that may be utilized in usual clinical practice.

Institution
MUSC
Recruitment Contact
Zerlinna Teague
8437920965
recruitment@musc.edu



-- OR --